Skip to main content

Table 3 Summary of toxicity in Trial 2 using the CDCA1 containing vaccine

From: Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer

Vaccine doses

1.0 mg (n=3)

3.0 mg (n=3)

Total patients (n=6)

 

Grade

Grade

(%)

 

1-2

3(4)

1-2

3(4)

  

Blood/bone marrow

      

   Anemia

2

0

2

0

4

(67)

   Thrombocytopenia

0

0

1

0

1

(17)

Hepatic

      

   Elevated AST

0

0

0

(1)

1

(17)

   Elevated ALT

0

0

0

(1)

1

(17)

Constitutional symptoms

      

   Fatigue

0

0

3

0

3

(50)

   Fever

1

0

1

0

2

(33)

Gastrointestinal

      

   Nausea/vomiting

0

0

2

0

2

(33)

   Anorexia

0

0

2

0

2

(33)

   Constipation

1

0

0

0

1

(17)

Dermatology/skin

      

   Rash

3

0

3

0

6

(100)

   Pruritus

3

0

2

0

5

(83)

   Reaction at the injection site

3

0

3

0

6

(100)